[Neoton in the treatment of myocardial infarct and unstable stenocardia].
A total of 485 patients with complicated myocardial infarction (MI) in the presence of concurrent abnormality and 104 patients with unstable angina (UA) were followed up. Intravenous infusion of neoton (phosphocreatine) in a dose of 70 g at day 1 and 36 g at days 2 and 3 of the onset was made in 96 patients with MI, 28 patients with UA took neoton in a daily dose of 30 g during 3 days. Control patients had conventional therapy, In UA, poor outcomes (death, MI, no effects, referral of patients for bypass surgery) were seen in 4 (14%) patients on the drug and in 18 (28%) in the controls (p > 0.05). In MI, more rapid disappearance of events (heart failure and tachyarrhythmias) was observed in the major group, the mortality being 23.9%, the incidence of cardiac ruptures 6.4 versus 33.6 and 12.6% respectively, in the control. It is concluded that large-dose neoton exerts positive action on the cause and outcome of UA and complicated MI.
Golikov
A P
AP
Riabinin
V A
VA
D000328:Adult; D000789:Angina, Unstable / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D010725:Phosphocreatine / Q000008:administration & dosage*; D013997:Time Factors; D016896:Treatment Outcome
D010725:Phosphocreatine
Neoton v lechenii infarkta miokarda i nestabil'noĭ stenokardii.